Occlutech Receives Positive Ruling in German Proceeding Initiated by AGA Medical
European developer of products for septal closure, today announced that the
district court of
obtained by AGA Medical against Occlutech’s sales and marketing activities
relating to the newly launched Figulla Flex ranges of ASD and PFO occluders.
The district court of
based on a request by AGA Medical, relying only on information provided by
AGA Medical. The injunction prohibited Occlutech from communicating the time
for the launch of the new Figulla Flex ASD and PFO occluders and the fact
that International markets and International distribution were not impacted
by a recent German patent ruling.
The request for an injunction by AGA was based on incorrect assumptions
regarding Occlutech’s R&D capabilities and about the International presence
of its associates and partners.
AGA Medical. In
associates and partners outside of
regarding the same patent. In
High Court of Justice,
infringe AGA’s patent EP 0808138.
The above Court decisions are not final and subject to appeal that
are/can be filed by AGA and/or Occlutech.
Occlusion devices are used to treat structural heart disease, including
structural heart defects and abnormalities such as Atrial Septal Defects,
(ASD), and Patent Foramen Ovale (PFO, an undesired channel between the
heart’s two atria, present in up to 25% of the population), in minimally
invasive, non-surgical procedures. The market for PFO occluders is expected
to expand significantly as the link between PFO and stroke, that is the third
most common cause of death, as well as severe migraine becomes increasingly
SOURCE Occlutech GmbH